EN
首页 资讯 期刊 导师 问答 求职 发Paper 文献直达 高级搜索 期刊列表
当前位置： X-MOL 学术 › Mol. Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Correction: Comprehensive review of CRISPR‑based gene editing: mechanisms, challenges, and applications in cancer therapy
Molecular Cancer ( IF 37.3 ) Pub Date : 2024-02-27 , DOI: 10.1186/s12943-024-01961-9
Mohammad Chehelgerdi , Matin Chehelgerdi , Milad Khorramian‑Ghahfarokhi , Marjan Shafieizadeh , Esmaeil Mahmoudi , Fatemeh Eskandari , Mohsen Rashidi , Asghar Arshi , Abbas Mokhtari‑Farsani

Correction: Mol Cancer 23, 9 (2024)

https://doi.org/10.1186/s12943-023-01925-5


Following publication of the original article [1], it has come to the author's attention that this article cites their work in an incorrect fashion and at least the related part of the paper raises some concern about the integrity of the reported information.

In Table 3 on clinical trials of CRISPR-based therapy of the manuscript, the authors cite our study (Ref 202 in the article, https://doi.org/10.1016/j.omtm.2022.03.018) and claim they demonstrated HPRT1-KO in cancer cells as a treatment strategy. Unfortunately, this statement does not reflect our study. They demonstrated for the first time that non-viral knock-in of CD19-specific CAR into primary human T cells is possible and effective with non-viral dsDNA templates (e.g. related to Fig. 11 of the Molecular Cancer article). This study was completely pre-clinical and had no relation to HPRT1.

After this perplexing finding, the corresponding author took some time to check other references of Table 3 and discovered that other references (such as References 201, 198, 197 that he checked) were also wrong. Glancing at other references in Table 3, it seems the authors cited predominantly review articles instead of original articles and at least some of the content was completely misaligned to the topic (e.g. Ref 198 cites a review on transplantation and GvhD; no relation to cancer therapy). Some of the related content is also non-sensical, suggesting either inexperience by the person preparing the table or potentially the use of a flawed AI tool. The correct Table 3 is given below.

Table 3 Clinical trials of CRISPR-based cancer therapy
Full size table

  1. Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, et al. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024;23:9. https://doi.org/10.1186/s12943-023-01925-5.

    Article PubMed PubMed Central Google Scholar

  2. Liu Q. World-first phase I clinical trial for CRISPR-Cas9 PD-1-edited T-cells in advanced nonsmall cell lung cancer. Glob Med Genet. 2020;7:073–4.

    Article Google Scholar

  3. Zhen S, Li X. Oncogenic human papillomavirus: application of CRISPR/Cas9 therapeutic strategies for cervical cancer. Cell Physiol Biochem. 2018:2455–66.

  4. Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med. 2020;26:732–40.

    Article CAS PubMed Google Scholar

  5. Ottaviano G, Georgiadis C, Gkazi SA, Syed F, Zhan H, Etuk A, et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci Transl Med. 2022;14.

  6. Khan A, Sarkar E. CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer. Cancer Treat Res Commun. 2022.

  7. Crispo F, Pietrafesa M, Condelli V, Maddalena F, Bruno G, Piscazzi A, et al. IDH1 Targeting as a new potential option for intrahepatic cholangiocarcinoma treatment—current state and future perspectives. Molecules. 2020.

  8. Mirgayazova R, Khadiullina R, Chasov V, Mingaleeva R, Miftakhova R, Rizvanov A, et al. Therapeutic editing of the TP53 gene: Is crispr/CAS9 an option? Genes (Basel). 2020:1–17.

  9. Chamberlain CA, Bennett EP, Kverneland AH, Svane IM, Donia M, Met Ö. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy. Mol Ther - Oncolytics. 2022;24:417–28.

    Article CAS PubMed PubMed Central Google Scholar

  10. Bamdad CC, Yuan Y, Specht JM, Stewart AK, Smagghe BJ, Lin SC-M, et al. Phase I/II first-in-human CAR T–targeting MUC1 transmembrane cleavage product (MUC1*) in patients with metastatic breast cancer. J Clin Oncol. 2022;40:TPS-1130.

    Article Google Scholar

  11. Alishah K, Birtel M, Masoumi E, Jafarzadeh L, Mirzaee HR, Hadjati J, et al. CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. J Transl Med. 2021;19.

  12. Hedrich V, Breitenecker K, Ortmayr G, Pupp F, Huber H, Chen D, et al. PRAME is a novel target of tumor-intrinsic Gas6/Axl activation and promotes cancer cell invasion in hepatocellular carcinoma. Cancers (Basel). 2023;15.

Download references

Authors and Affiliations

  1. Novin Genome (NG) Lab, Research and Development Center for Biotechnology, Shahrekord, Iran

    Mohammad Chehelgerdi, Matin Chehelgerdi & Abbas Mokhtari‑Farsani

  2. Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran

    Mohammad Chehelgerdi, Matin Chehelgerdi & Esmaeil Mahmoudi

  3. Division of Biotechnology, Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran

    Milad Khorramian‑Ghahfarokhi

  4. Department of Chemistry, Shahid Bahonar University of Kerman, Kerman, Iran

    Marjan Shafieizadeh

  5. Faculty of Molecular and Cellular Biology ‑Genetics, Islamic Azad University of Falavarjan, Isfahan, Iran

    Fatemeh Eskandari

  6. Department Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

    Mohsen Rashidi

  7. The Health of Plant and Livestock Products Research Center, Mazandaran University of Medical Sciences, Sari, Iran

    Mohsen Rashidi

  8. Young Researchers and Elite Club, Najafabad Branch, Islamic Azad University, Najafabad, Iran

    Asghar Arshi

  9. Department of Biology, Nourdanesh Institute of Higher Education, Meymeh, Isfahan, Iran

    Abbas Mokhtari‑Farsani

Authors
  1. Mohammad ChehelgerdiView author publications

    You can also search for this author in PubMed Google Scholar

  2. Matin ChehelgerdiView author publications

    You can also search for this author in PubMed Google Scholar

  3. Milad Khorramian‑GhahfarokhiView author publications

    You can also search for this author in PubMed Google Scholar

  4. Marjan ShafieizadehView author publications

    You can also search for this author in PubMed Google Scholar

  5. Esmaeil MahmoudiView author publications

    You can also search for this author in PubMed Google Scholar

  6. Fatemeh EskandariView author publications

    You can also search for this author in PubMed Google Scholar

  7. Mohsen RashidiView author publications

    You can also search for this author in PubMed Google Scholar

  8. Asghar ArshiView author publications

    You can also search for this author in PubMed Google Scholar

  9. Abbas Mokhtari‑FarsaniView author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Chehelgerdi.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chehelgerdi, M., Chehelgerdi, M., Khorramian‑Ghahfarokhi, M. et al. Correction: Comprehensive review of CRISPR‑based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer 23, 43 (2024). https://doi.org/10.1186/s12943-024-01961-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12943-024-01961-9

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative



中文翻译：
更正：基于 CRISPR 的基因编辑的全面回顾：癌症治疗中的机制、挑战和应用

更正：摩尔癌症 23, 9 (2024)

https://doi.org/10.1186/s12943-023-01925-5


在原始文章[1]发表后，作者注意到这篇文章以不正确的方式引用了他们的工作，并且至少论文的相关部分引起了对所报告信息完整性的一些担忧。

在手稿的基于 CRISPR 疗法的临床试验表 3 中，作者引用了我们的研究（文章中的参考文献 202，https://doi.org/10.1016/j.omtm.2022.03.018）并声称他们证明了 HPRT1 - 敲除癌细胞作为治疗策略。不幸的是，这个陈述并不反映我们的研究。他们首次证明，使用非病毒dsDNA模板将CD19特异性CAR非病毒敲入原代人类T细胞是可能且有效的（例如与Molecular Cancer文章的图11​​相关）。这项研究完全是临床前研究，与 HPRT1 无关。

在这个令人困惑的发现之后，通讯作者花了一些时间检查表3的其他参考文献，发现其他参考文献（例如他检查的参考文献201、198、197）也是错误的。浏览表 3 中的其他参考文献，作者似乎主要引用了评论文章而不是原始文章，并且至少有一些内容与主题完全不相符（例如参考文献 198 引用了关于移植和 GvhD 的评论；与癌症治疗无关） ）。一些相关内容也毫无意义，这表明要么是准备表格的人缺乏经验，要么是使用了有缺陷的人工智能工具。下面给出了正确的表 3。

表3 基于CRISPR的癌症治疗的临床试验
全尺寸桌子

  1. Chehelgerdi M、Chehelgerdi M、Khorramian-Ghahfarokhi M 等。基于 CRISPR 的基因编辑的全面综述：机制、挑战和在癌症治疗中的应用。摩尔癌症。2024；23：9。https://doi.org/10.1186/s12943-023-01925-5。

    文章 PubMed PubMed Central Google Scholar

  2. Liu Q. 世界首个 CRISPR-Cas9 PD-1 编辑 T 细胞治疗晚期非小细胞肺癌的 I 期临床试验。全球医学基因。2020；7：073–4。

    文章谷歌学术

  3. Chen S, Li X. 致癌人乳头瘤病毒：CRISPR/Cas9 治疗策略在宫颈癌中的应用。细胞生理生物化学。2018：2455–66。

  4. 卢Y，薛J，邓T，周X，于K，邓L，等。CRISPR 编辑的 T 细胞在难治性非小细胞肺癌患者中的安全性和可行性。纳特医学。2020；26：732–40。

    文章 CAS PubMed 谷歌学术

  5. Ottaviano G、Georgiadis C、Gkazi SA、Syed F、Zhan H、Etuk A 等。CRISPR 工程改造的 CAR19 通用 T 细胞治疗儿童难治性 B 细胞白血病的 1 期临床试验。科学翻译医学。2022；14。

  6. Khan A、Sarkar E. CRISPR/Cas9 鼓励 CAR-T 细胞免疫疗法报告针对癌症的高效、安全的临床结果。癌症治疗研究。2022 年。

  7. Crispo F、Pietrafesa M、Condelli V、Maddalena F、Bruno G、Piscazzi A 等。IDH1 靶向作为肝内胆管癌治疗的新潜在选择——现状和未来前景。分子。2020.

  8. Mirgayazova R、Khadiullina R、Chasov V、Mingaleeva R、Miftakhova R、Rizvanov A 等。TP53 基因的治疗性编辑：crispr/CAS9 是一种选择吗？基因（巴塞尔）。2020：1-17。

  9. 张伯伦 CA、贝内特 EP、Kverneland AH、Svane IM、多尼亚 M、Met Ö。用于基于肿瘤浸润淋巴细胞的过继性 T 细胞治疗的高效 PD-1 靶向 CRISPR-Cas9。Mol Ther - 溶瘤药。2022；24：417–28。

    文章 CAS PubMed PubMed Central Google Scholar

  10. Bamdad CC、Yuan Y、Specht JM、Stewart AK、Smagghe BJ、Lin SC-M 等。针对转移性乳腺癌患者的 I/II 期首个人体 CAR T 靶向 MUC1 跨膜裂解产物 (MUC1*)。J 临床肿瘤学杂志。2022；40：TPS-1130。

    文章谷歌学术

  11. Alisah K、Birtel M、Masoumi E、Jafarzadeh L、Mirzaee HR、Hadjati J 等。CRISPR/Cas9介导的TGFβRII破坏增强人嵌合抗原受体T细胞的体外抗肿瘤功效。翻译医学杂志。2021；19。

  12. Hedrich V、Breitenecker K、Ortmayr G、Pupp F、Huber H、Chen D 等人。PRAME 是肿瘤内在 Gas6/Axl 激活的新靶点，可促进肝细胞癌中的癌细胞侵袭。癌症（巴塞尔）。2023；15。

下载参考资料

作者和单位

  1. Novin 基因组 (NG) 实验室，生物技术研发中心，Shahrekord，伊朗

    穆罕默德·切赫尔格迪、马丁·切赫尔格迪和阿巴斯·莫赫塔里·法尔萨尼

  2. 伊朗沙赫勒科德伊斯兰阿扎德大学沙赫勒科德分校青年研究员和精英俱乐部

    穆罕默德·切赫尔格迪、马丁·切赫尔格迪和埃斯梅尔·马哈茂迪

  3. 设拉子大学兽医学院病理生物学系生物技术部，伊朗设拉子

    米拉德·霍拉米安-加法罗基

  4. 化学系，克尔曼沙希德巴霍纳尔大学，伊朗克尔曼

    马里安·沙菲扎德

  5. 伊朗伊斯法罕法拉瓦尔詹伊斯兰阿扎德大学分子和细胞生物学-遗传学系

    法特梅·埃斯坎达里

  6. 伊朗萨里马赞德兰医科大学医学院药理学系

    莫森·拉希迪

  7. 伊朗马赞德兰医科大学植物和畜牧产品健康研究中心，萨里，伊朗

    莫森·拉希迪

  8. 伊朗纳贾法巴德伊斯兰阿扎德大学纳贾法巴德分校青年研究员和精英俱乐部

    阿斯加尔·阿尔什

  9. 努尔达内什高等教育学院生物学系，Meymeh，伊斯法罕，伊朗

    阿巴斯·莫赫塔里-法尔萨尼

作者
  1. Mohammad Chehelgerdi查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  2. Matin Chehelgerdi查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  3. Milad Khorramian-Ghahfarokhi查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  4. Marjan Shafieizadeh查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  5. Esmaeil Mahmoudi查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  6. Fatemeh Eskandari查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  7. Mohsen Rashidi查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  8. Asghar Arshi查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  9. Abbas Mokhtari‑Farsani查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

通讯作者

通讯作者：Mohammad Chehelgerdi。

开放获取本文根据知识共享署名 4.0 国际许可证获得许可，该许可证允许以任何媒介或格式使用、共享、改编、分发和复制，只要您对原作者和来源给予适当的认可，提供知识共享许可的链接，并指出是否进行了更改。本文中的图像或其他第三方材料包含在文章的知识共享许可中，除非材料的出处中另有说明。如果文章的知识共享许可中未包含材料，并且您的预期用途不受法律法规允许或超出了允许的用途，则您需要直接获得版权所有者的许可。要查看此许可证的副本，请访问 http://creativecommons.org/licenses/by/4.0/。知识共享公共领域奉献豁免 (http://creativecommons.org/publicdomain/zero/1.0/) 适用于本文中提供的数据，除非数据的信用额度中另有说明。

转载和许可

检查更新。 通过 CrossMark 验证货币和真实性

引用这篇文章

Chehelgerdi, M.、Chehelgerdi, M.、Khorramian-Ghahfarokhi, M.等人。更正：基于 CRISPR 的基因编辑的全面回顾：癌症治疗中的机制、挑战和应用。摩尔癌症 23 , 43 (2024)。https://doi.org/10.1186/s12943-024-01961-9

下载引文

  • 发表：

  • DOI ：https://doi.org/10.1186/s12943-024-01961-9

分享此文章

您与之分享以下链接的任何人都可以阅读此内容：

抱歉，本文目前没有可共享的链接。

由 Springer Nature SharedIt 内容共享计划提供
更新日期：2024-02-27
  点击分享   查看原文
点击收藏
公开下载
阅读更多本刊最新论文 本刊介绍/投稿指南
down
wechat
bug